NeuroScientific Biopharmaceuticals (NSB) H2 2025 earnings summary

Executive summary

• Focused on R&D of biomedical products for neurodegenerative conditions, with the acquisition of Isopogen WA and its StemSmart™ technology completed in June 2025.

• Initiated a Special Access Scheme for treating fistulising Crohn's disease using StemSmart™.

• Significant board and management changes, including new Chair and CEO appointments.

Financial highlights

• Net loss of $1,845,513 for FY25, compared to a $324,210 profit in FY24.

• Total income dropped to $166,078 from $2,390,765 year-over-year, mainly due to lower R&D tax incentives.

• Cash and term deposits at year-end were $7,265,769, up from $4,954,142 in FY24.

• Net working capital surplus of $7,246,156 at 30 June 2025.

• No dividends declared or paid.

Outlook and guidance

• Ongoing net losses expected as clinical development and GMP manufacturing of StemSmart™ progresses.

• Directors believe current cash reserves are sufficient to fund operations for at least 12 months.